Skip to content
RCELAVITA Medical, Inc.

Earnings

When AVITA Medical, Inc. reports, what it reported each quarter, and how the stock took the results.

24 quarters. Sep 30, 2018 to Sep 30, 2026. USD.

Next results · Q4 2026Projected

Feb 11, after the close

Thu, Feb 11, 2027in 85 days

Projected from its last 8 releases. The company has not named the day yet.

Quarter
Q4 2026 · Ends about Dec 31, 2026
10-K window
Feb 10 – Mar 1

Read against Q4 2025

The same quarter a year earlier, the figures the next ones will be compared with. Thaler holds no estimates.

Revenue
$17.62M
Revenue, change from a year earlier: Q3 2026 +53.1%, Q2 2026 +17.8%, Q1 2026 +4.0%, Q4 2025 −4.3%
Net income
-$11.62M
Net income, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q4 2025 n/m
EPS
—
EPS, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q3 2025 n/m

Quarter by quarter

Q3 2026$26.11M+53.1% vs Q3 2025

Latest results

  1. Q3 2026Nov 5, 2026, after the closeThe release+5.5%by the close of Nov 6
    Revenue
    $26.11M
    +53.1%
    Net income
    -$6.22M
    N/M
    EPS
    -$0.20
    N/M
    Based on its third-quarter performance, AVITA Medical is raising its full-year 2026 revenue guidance to $92 million to $94 million, from $86 million to $89 million.
  2. Q2 2026Aug 6, 2026, after the closeThe release+63.6%by the close of Aug 7
    Revenue
    $21.70M
    +17.8%
    Net income
    -$7.66M
    N/M
    EPS
    -$0.25
    N/M
  3. Q1 2026May 14, 2026, after the closeThe release+4.6%by the close of May 15
    Revenue
    $19.25M
    +4.0%
    Net income
    -$10.61M
    N/M
    EPS
    -$0.35
    N/M
  4. Q4 2025Feb 12, 2026, after the closeThe release+11.8%by the close of Feb 13
    Revenue
    $17.62M
    −4.3%
    Net income
    -$11.62M
    N/M
    EPS
    —
    —

All quarters

PeriodEndedAnnouncedFiledLagFormRevenueΔ yoyEPS dil.MoveSource trail
FY 2026
Q3 2026Sep 30, 2026Nov 5, 2026 · after-hoursNov 5, 202636 d10-Q$26.11M+53.1%-$0.20+5.5%
Q2 2026Jun 30, 2026Aug 6, 2026 · after-hoursAug 6, 202637 d10-Q$21.70M+17.8%-$0.25+63.6%
Q1 2026Mar 31, 2026May 14, 2026 · after-hoursMay 14, 202644 d10-Q$19.25M+4.0%-$0.35+4.6%
FY 2025
Q4 2025derivedDec 31, 2025Feb 12, 2026 · after-hoursFeb 12, 202643 d10-K$17.62M−4.3%—+11.8%
Q3 2025Sep 30, 2025Nov 6, 2025 · after-hoursNov 6, 202537 d10-Q$17.06M−12.7%-$0.46+9.6%
Q2 2025Jun 30, 2025Aug 7, 2025 · after-hoursAug 8, 202539 d10-Q$18.42M+21.2%-$0.3821.0%
Q1 2025Mar 31, 2025May 8, 2025 · after-hoursMay 8, 202538 d10-Q$18.51M+66.7%-$0.5325.0%
FY 2024
Q4 2024derivedDec 31, 2024Feb 13, 2025 · after-hoursFeb 13, 202544 d10-K$18.41M+29.7%—+20.3%
Q3 2024Sep 30, 2024Nov 7, 2024 · after-hoursNov 7, 202438 d10-Q$19.55M+43.2%-$0.623.9%
Q2 2024Jun 30, 2024Aug 8, 2024 · after-hoursAug 8, 202439 d10-Q$15.20M+29.3%-$0.60—
Q1 2024Mar 31, 2024May 13, 2024 · after-hoursMay 13, 202443 d10-Q$11.10M+5.3%-$0.73—
Earlier years, FY 2019 to FY 2023

Move: the stock from the last close before the release to the first close after it. Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Source filings

10-QNov 5, 2026449873
10-QAug 6, 2026338101
10-QMay 14, 2026224107
10-KFeb 12, 2026049031
10-QNov 6, 2025269597
10-QAug 8, 2025000014
10-QMay 8, 2025066994
10-KFeb 13, 2025020026
10-QNov 7, 2024123326
10-QAug 8, 2024093964

Provenance

ProvenanceData status and checks

AVITA Medical, Inc. · CIK 1762303 · Engraved from SEC EDGAR